The pharmaceutical company has experienced sales growth over the past five years.On November 17, 2025, financial services firm Westshore Wealth, LLC disclosed a new position in Amneal Pharmaceuticals (AMRX +0.00%), acquiring 1,381,910 shares valued at approximately $13.83 million.Westshore initiated a stake in Amneal in the third quarter, buying 1,381,910 shares.The transaction accounted for 4.73% of Westshore Wealth's 13F reportable assets under management.Post-trade, Westshore's total stake in Amneal was ...

Intel was the best-performing stock in the S&P 500 Friday. JIMMY BEUNARDEAU / Hans Lucas / AFP / Getty Images Close Key Takeaways A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high- flying pharmaceutical stock reversed some of its recent gains. Major U.S. equities indexes rose in Friday's shortened trading session to register their best week since June, though the Nasdaq logged its first losing month since March. The S&P 500 rose 0.5%, the Dow added 0 ...

The U.S. stock market concluded a volatile November with a positive, albeit abbreviated, trading session on Black Friday, November 28, 2025. Major indexes extended their winning streaks for the week, pushing higher despite an early close at 1:00 PM ET for equities and 2:00 PM ET for the bond market, a traditional observance following the Thanksgiving holiday. The shortened trading day saw investors digesting a mix of company-specific news and continued optimism surrounding potential Federal Reserve policy s ...

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 84 unusual trades.Delving into the details, we found 27% of traders were bullish, while 51% showed bearish tendencies. Out of all the trades we spotted, 26 were puts, with a value of $2,090,541, and 58 were calls, valued at $10,418,102.Expected Price MovementsTaking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a pric ...

Key Takeaways ANIP is seeing sharp rare-disease growth driven by Cortrophin Gel and steady generics performance.Cortrophin Gel sales are up 70% YTD and projected to rise 75-78% for 2025, offsetting softness elsewhere.AMRX benefits from diversified segments, though generics pricing pressure and mixed specialty trends persist.ANI Pharmaceuticals (ANIP) and Amneal Pharmaceuticals (AMRX) are both generic drugmakers, but their overall business models differ.ANIP’s operations are split between rare disease therap ...

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telix Pharmaceuticals Limited (NASDAQ:TLX) and Firefly Aerospace Inc. (NASDAQ:FLY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Telix Pharmaceuticals Limited (NASDAQ:TLX) Class ...

Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025NEW YORK, Nov. 28, 2025 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025. Editors in chief play one of the most pivotal roles in modern media. As the ultimate decision-makers for what appears on the page or on screen, they guide the editorial vision, shape content strategy, and uphold the standards of accuracy, fairness, and creativity that define trusted journalism. These ...

Key Takeaways JNJ's oncology sales rose 20.6% to $18.52B on strong growth of key cancer drugs.JNJ targets $50B in oncology sales by decade-end.A $3.05B deal for Halda Therapeutics adds targeted cancer medicines to JNJ's portfolio.Johnson & Johnson (JNJ) is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors.Its Oncology segment, at present, comprises around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis ...

Group 1: Market Sentiment and Trends - CNBC host Jim Cramer has become more cautious toward AI and data center stocks due to increasing insider selling and borrowing activity, indicating a shift from the previous era of "magical investing" [1] - Cramer has revised his outlook on data center companies, stating that the favorable investment period is over and has declared it "dead" [1] Group 2: Stock Recommendations - Cramer recommends holding shares of TJX Companies (NYSE:TJX), emphasizing its strength in a downturn, with the stock up 21% this year and a dividend yield of about 1.2% [3] - Energy Transfer LP Unit (NYSE:ET) is highlighted as a high-yield dividend stock, despite being down 13% this year and missing Q3 estimates, with a dividend yield of approximately 7.8% [4] - Procter & Gamble (NYSE:PG) is viewed as an attractive investment opportunity in a down market, offering a dividend yield of 2.85% and demonstrating strong operational efficiency [5][6] - Johnson & Johnson (NYSE:JNJ) received a bullish outlook following FDA approval of its Caplyta drug for treating major depressive disorder [6][8]

We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent on Wednesday to end at $3.86 apiece as investors cheered the new price set by the Health Department for its bowel treatment, which fell in line with its expectations. In a regulatory filing, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) said that the US Department of Health and Human Services released the ma ...